LB Pharmaceuticals Inc Common Stock reported earnings of -$ 1.79 per LBRX share on Nov 5, 2026, beating analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 1.62 |
| Earnings Per Share (Surprise) | -$ 1.79 (-$ 0.17) |
| Last Year's EPS | -$ 0.83 |
| EPS YoY Change |
Out of the last 6 earnings reporting periods, LB Pharmaceuticals Inc Common Stock beat analysts’ expectations 1 times and fell short of expectations 3 time(s). LB Pharmaceuticals Inc Common Stock reported earnings per share of -$ 1.79 in the last report falling to reach an estimated EPS of -$ 1.62 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 1.62 | -$ 1.79 | -$ 0.61 | |
| Aug 11, 2026 | -$ 0.80 | -$ 1.71 | -$ 1.44 | |
| May 12, 2026 | -$ 0.75 | -$ 0.67 | - | - |
| Mar 26, 2026 | -$ 0.45 | -$ 0.45 | - | - |
| Nov 6, 2025 | -$ 0.57 | -$ 0.61 | - | - |
| Sep 8, 2025 | - | -$ 1.44 | - | - |
LB Pharmaceuticals Inc Common Stock’s stock was trading at $ 40.85 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, LBRX’s price increased to $ 42.01 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 1.79 | $ 40.85 | $ 42.01 | |
| Aug 11, 2026 | -$ 1.71 | $ 45.85 | $ 45.38 | |
| May 12, 2026 | -$ 0.67 | $ 32.70 | $ 32.31 | |
| Mar 26, 2026 | -$ 0.45 | $ 24.21 | $ 23.84 | |
| Nov 6, 2025 | -$ 0.61 | $ 16.20 | $ 15.35 | |
| Sep 8, 2025 | -$ 1.44 | $ 17.30 |
LB Pharmaceuticals Inc Common Stock released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
LB Pharmaceuticals Inc Common Stock missed analysts’ expectations during the last earnings period by
